glofitamab,Obinutuzumab 
roche
['lymsm', 'dlbcl', 'glofitamab', 'lymphoma']
congress #asco22 | speaks about the results of a phase ii trial of glofitamab in patients with r/r #dlbcl treated with 2 lines of therapy. orr &amp; cr rates by irc were 51.6% &amp; 39.4%, respectively with a median follow-up of 12.6 months #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm